Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)Elizabeth Finger, Adam L. Boxer, Scott Berry et al.|Alzheimer s Research & Therapy|2018Cited by 35
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trialKristy Coleman, Elizabeth Finger, Scott Berry et al.|The Lancet Neurology|2025Cited by 17
Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypesAitana Sogorb‐Esteve, Stefano Gazzina, Lize C. Jiskoot et al.|Science Translational Medicine|2025Cited by 13
Issue InformationKenneth L. Tyler, Markus Otto, Christopher Butler et al.|Annals of Neurology|2021Cited by 0
Developing a mass spectrometric assay to measure granulin peptides in CSF for progranulin‐associated frontotemporal dementiaImogen J. Swift, Johan Gobom, Sophia Weiner et al.|Alzheimer s & Dementia|2023Cited by 0